Trial Profile
A Randomized Controlled Study to Evaluate the Efficacy and Safety of Endocrine Therapy Plus Chemotherapy Versus Chemotherapy Alone as the Neoadjuvant Therapy in the Treatment of ER-positive, HER2-negative Breast Cancer (IIa-IIIc)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Leuprorelin (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Breast cancer; Ductal carcinoma; HER2 negative breast cancer
- Focus Therapeutic Use
- 30 Oct 2017 Status changed from active, no longer recruiting to completed.
- 05 Dec 2016 New trial record